Crescent Biopharma Posts $289.4M Cash, Runway Into H2 2028 as Q3 Loss Widens
CBIO sits 65% above its 52-week low of $8.72.
Summary
Crescent ended September with $289.4M in cash and equivalents, including $133.4M in net proceeds from its July offering, and says that funds operations into H2 2028. The Q3 net loss widened to $37.7M from $24.6M a year earlier, with R&D up to $34.3M from $20.3M as clinical development expanded. That burn rate is the number that matters: the runway claim rests on spending not accelerating much beyond current levels. Operationally, ASCEND has dosed over 125 patients with monotherapy data, including first-line NSCLC, still guided to Q1 2027, and the first patient has been dosed in the global Phase 1/2 APOLLO trial. This follows the October 15 8-K laying out the clinical timeline and the October 5 FDA clearance for CR-002. The Q1 2027 ASCEND readout is the next binary event for the stock.
At the time of this announcement, CBIO was trading at $14.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $533.8M. The 52-week trading range was $8.72 to $27.41. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.